Review
Copyright ©The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Cardiol. Nov 26, 2015; 7(11): 707-718
Published online Nov 26, 2015. doi: 10.4330/wjc.v7.i11.707
Translational research of adult stem cell therapy
Gen Suzuki
Gen Suzuki, Division of Cardiovascular Medicine, University at Buffalo, Clinical and Translational Research Center, Buffalo, NY 14203, United States
Author contributions: Suzuki G wrote the paper and performed data collection.
Supported by New York State NYSTEM foundation, No. N08G-433.
Conflict-of-interest statement: Authors declare no conflict of interests for this article.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Gen Suzuki, MD, PhD, Associate Professor of Medicine, Division of Cardiovascular Medicine, University at Buffalo, Clinical and Translational Research Center, 875 Ellicott Street, Buffalo, NY 14203, United States. gsuzuki@buffalo.edu
Telephone: +1-716-8292710 Fax: +1-716-8292665
Received: May 28, 2015
Peer-review started: June 1, 2015
First decision: August 4, 2015
Revised: August 20, 2015
Accepted: September 25, 2015
Article in press: September 28, 2015
Published online: November 26, 2015
Processing time: 186 Days and 2.2 Hours
Abstract

Congestive heart failure (CHF) secondary to chronic coronary artery disease is a major cause of morbidity and mortality world-wide. Its prevalence is increasing despite advances in medical and device therapies. Cell based therapies generating new cardiomyocytes and vessels have emerged as a promising treatment to reverse functional deterioration and prevent the progression to CHF. Functional efficacy of progenitor cells isolated from the bone marrow and the heart have been evaluated in preclinical large animal models. Furthermore, several clinical trials using autologous and allogeneic stem cells and progenitor cells have demonstrated their safety in humans yet their clinical relevance is inconclusive. This review will discuss the clinical therapeutic applications of three specific adult stem cells that have shown particularly promising regenerative effects in preclinical studies, bone marrow derived mesenchymal stem cell, heart derived cardiosphere-derived cell and cardiac stem cell. We will also discuss future therapeutic approaches.

Keywords: Congestive heart failure; Adult stem cells; Mesenchymal stem cell; Cardiosphere-derived cell; Cardiac stem cell

Core tip: Cell-based therapy emerged as a new approach to restore damaged heart function. Although cell therapy in experimental animal models is promising, beneficial effects in clinical trials are variable. This review summarizes recent preclinical and clinical applications on three specific adult stem cells (bone marrow derived mesenchymal stem cell, heart derived cardiosphere-derived cells and cardiac stem cell) and discuss about future approaches.